Inclisiran (sodium)

Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD) [1][2][3].

Product Specifications

Product Name Alternative

ALN-PCSsc (sodium)

UNSPSC

12352208

Target

Caspase; Interleukin Related; NOD-like Receptor (NLR) ; PCSK9; PPAR; Pyroptosis; Small Interfering RNA (siRNA)

Type

Oligonucleotides

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/inclisiran-sodium.html

Purity

98.91

Solubility

10 mM in H2O

Smiles

[Inclisiran(sodium)]

Molecular Formula

C529H707F12N176O316P43S6.xNa

Molecular Weight

16339.6 (free acid)

References & Citations

[1]Constantine E Kosmas, et al. Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential. Ther Clin Risk Manag. 2020 Oct 28;16:1031-1037.|[2]Kong N, et al. PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis. Ann Transl Med. 2022;10 (22) :1205. |[3]Wang Z, et al. Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264.7 macrophages via activating the PPARγ pathway. Autoimmunity. 2022 Jun;55 (4) :223-232.